OptimizeRx Corporation

NASDAQ:OPRX

Medical - Healthcare Information Services

Healthcare
$7.31 -0.98%

-$0.05 today

Market cap
$138.21M
Beta
1.10
P/E (TTM)
13.8
EPS (TTM)
$0.36
52W Low $4.57High $22.25

Volume 0.18M

Average 0.47M

OPRX Common Stock Repurchased

Cash spent buying back the company's own shares.

OptimizeRx CorporationNASDAQ: OPRX

Common Stock Repurchased · Q1 FY2026 · quarter ended Mar 2026

Common stock repurchased turns positive

Q1 FY2026 common stock repurchased was $0, compared with -$87K a year earlier. Trailing-twelve-month common stock repurchased was -$101K.

Context

  • Common stock repurchased amounted to 0.0% of revenue in FY2025, down 1.0 pp from a year earlier.
  • Common stock repurchased increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock repurchased holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$25.25K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0+100.0% YoY
LTMMar 2026
-$101K-88.2% YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year+100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
+100.0%

Common Stock Repurchased vs competitors

How OPRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock repurchased is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -88.2% is the lowest of 6, against a peer median of -27.9%.
  • Common stock repurchased amounts to 0.1% of revenue for OPRX, versus a peer median of 0.9%.
OPRX Competitors
Common Stock Repurchased for OPRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DHDefinitive Healthcare Corp.LTM Mar 2026$28.3M USD-35.0%—11.9%
NRCNational Research CorporationLTM Mar 2026$17.2M USD-17.6%-9.9%12.4%
SPOKSpok Holdings, Inc.LTM Mar 2026$1.93M USD-32.2%+32.9%1.4%
TBRGTruBridge, Inc.LTM Mar 2026$1.38M USD-27.9%-45.4%0.4%
NAKANakamoto Inc.LTM Mar 2026$871.4K USD+2610.9%—22.2%
OPRXOptimizeRx CorporationLTM Mar 2026$101K USD-88.2%—0.1%
SOPHSOPHiA GENETICS S.A.LTM Mar 2026$0 USD——0.0%
SLPSimulations Plus, Inc.LTM Feb 2026$0 USD——0.0%
DRUGBright Minds Biosciences Inc.LTM Mar 2026CA$0 CAD———
RXSTRxSight, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding OPRX) —-27.9%-9.9%0.9%

Competitors are the stored peer set for OPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income378.08K(11.44M)(17.57M)(20.11M)5.13M
Depreciation & Amortization1.97M2.02M2.4M4.33M4.33M
Deferred Income Tax0001.45M1.21M
Stock-Based Compensation5.49M15.75M13.72M11.47M6.96M
Change in Working Capital(7.19M)3.96M(15.55M)921K816K
Accounts Receivables(6.99M)2.28M(8.71M)(2.17M)460K
Inventory00000
Accounts Payables(603.09K)555.4K195K(72K)(520K)
Other Working Capital408.65K1.12M(7.03M)3.16M876K
Other Non-Cash Items80K363.51K9.76M6.83M264K
Operating Cash Flow726.04K10.65M(7.24M)4.89M18.72M
Capital Expenditures(486K)(244.57K)(871K)(112K)(58K)
Acquisitions (Net)0(2M)(80.41M)00
Purchases of Investments0(55.93M)(162.78M)00
Sales of Investments00218.71M00
Other Investing Activities(385.68K)(163.56K)(774K)(338K)126K
Investing Cash Flow(486K)(58.18M)(25.34M)(450K)68K
Debt Repayment0036.02M(4M)(8M)
Common Stock Issued70.67M000352K
Common Stock Repurchased0(20.02M)(7.52M)(911K)0
Dividends Paid00000
Other Financing Activities3.25M1.07M(278K)0(1.15M)
Financing Cash Flow73.92M(18.95M)28.22M(4.91M)(8.8M)
Effect of Forex Changes00000
Net Change in Cash74.16M(66.47M)(4.36M)(472K)9.99M
Free Cash Flow240.04K10.41M(8.11M)4.78M18.66M

OptimizeRx Corporation

NASDAQ:OPRX

Intrinsic Alpha fair value

Locked

Current Price

$7.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.